Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes

US FDA's Gastrointestinal Drugs Advisory Committee says higher dosing regimens can be used despite agency worries about safety with long-term use.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers